TDP-43 Proteinopathy Investment Landscape

TDP-43 Proteinopathy Investment

Overview

This page summarizes trial-derived R&D investment signals for TDP-43 proteinopathy therapeutics, primarily focused on [Amyotrophic Lateral Sclerosis (ALS)](/diseases/amyotrophic-lateral-sclerosis) and [Frontotemporal Dementia (FTD)](/diseases/frontotemporal-dementia), the two conditions where TDP-43 pathology is most prominent. TDP-43 (TAR DNA-binding protein 43) aggregates are found in ~95% of ALS cases and ~50% of FTD cases [@neumann2006][@arai2006].

Portfolio Metrics

| Metric | ALS | FTD |
|---|---|---:|
| Total tracked trials | 750 | 113 |
| Active trials | 189 (25.2%) | 31 (27.4%) |
| Completed trials | 351 (46.8%) | 41 (36.3%) |
| Late-stage (Phase 3/4) | 70 (9.3%) | 6 (5.3%) |
| Phase 1/2 programs | 275 (36.7%) | 18 (15.9%) |

Combined TDP-43 Pipeline: 863 trials across ALS and FTD

Therapeutic Approach Categories

Small Molecule Approaches

| Approach | ALS Trials | FTD Trials | Status |
|---|---|---|---|
| Mitochondrial modulators | 525 | Limited | Most advanced |
| Genetic targeting | 52 | 12 | Growing |
| Neuroinflammation targets | 10 | 8 | Early stage |
| Neurotransmitter modulation | 5 | 3 | Established |
| Growth factor therapy | 6 | 2 | Early stage |

Gene Therapy and Antibody Approaches

TDP-43 Proteinopathy Investment

Overview

This page summarizes trial-derived R&D investment signals for TDP-43 proteinopathy therapeutics, primarily focused on [Amyotrophic Lateral Sclerosis (ALS)](/diseases/amyotrophic-lateral-sclerosis) and [Frontotemporal Dementia (FTD)](/diseases/frontotemporal-dementia), the two conditions where TDP-43 pathology is most prominent. TDP-43 (TAR DNA-binding protein 43) aggregates are found in ~95% of ALS cases and ~50% of FTD cases [@neumann2006][@arai2006].

Portfolio Metrics

| Metric | ALS | FTD |
|---|---|---:|
| Total tracked trials | 750 | 113 |
| Active trials | 189 (25.2%) | 31 (27.4%) |
| Completed trials | 351 (46.8%) | 41 (36.3%) |
| Late-stage (Phase 3/4) | 70 (9.3%) | 6 (5.3%) |
| Phase 1/2 programs | 275 (36.7%) | 18 (15.9%) |

Combined TDP-43 Pipeline: 863 trials across ALS and FTD

Therapeutic Approach Categories

Small Molecule Approaches

| Approach | ALS Trials | FTD Trials | Status |
|---|---|---|---|
| Mitochondrial modulators | 525 | Limited | Most advanced |
| Genetic targeting | 52 | 12 | Growing |
| Neuroinflammation targets | 10 | 8 | Early stage |
| Neurotransmitter modulation | 5 | 3 | Established |
| Growth factor therapy | 6 | 2 | Early stage |

Gene Therapy and Antibody Approaches

The TDP-43 proteinopathy field is increasingly focusing on:

• Antisense oligonucleotides (ASOs): Targeting TARDBP gene expression
• Gene replacement: Delivering functional TDP-43
• Antibody therapies: Anti-TDP-43 monoclonal antibodies
• Small molecules: Aggregation inhibitors, [autophagy](/entities/autophagy) enhancers

Trial Status Distribution

ALS Trial Status

| Category | Trial Count | Share |
|---|---|---:|
| Active/Recruiting | 189 | 25.2% |
| Recruiting | 122 | 16.3% |
| Not Yet Recruiting | 27 | 3.6% |
| Active Not Recruiting | 34 | 4.5% |
| Enrolling By Invitation | 6 | 0.8% |
| Historical | 561 | 74.8% |
| Completed | 351 | 46.8% |
| Terminated | 66 | 8.8% |
| Withdrawn | 28 | 3.7% |
| Unknown | 100 | 13.3% |

FTD Trial Status

| Category | Trial Count | Share |
|---|---|---:|
| Active/Recruiting | 31 | 27.4% |
| Historical | 82 | 72.6% |
| Completed | 41 | 36.3% |
| Terminated | 12 | 10.6% |
| Withdrawn | 8 | 7.1% |

Mechanism Cluster Distribution

| Mechanism Cluster | ALS Trials | Primary Focus |
|---|---|---|
| Mitochondrial biology | 525 (70.0%) | Energy metabolism, oxidative stress |
| Genetic / gene-targeted | 52 (6.9%) | SOD1, [C9orf72](/entities/c9orf72), TARDBP |
| Amyloid biology | 14 (1.9%) | TDP-43 aggregation |
| Neuroinflammation | 10 (1.3%) | Microglial modulation |
| Synaptic function | 7 (0.9%) | Neuroprotection |
| Growth factor | 6 (0.8%) | Neuronal support |

Key Insight: Mitochondrial dysfunction dominates the ALS pipeline (70%), reflecting the central role of energy failure in TDP-43 proteinopathy [@cozzolino2019].

Sponsor Landscape

Top Academic Sponsors (ALS)

| Sponsor | Trial Count |
|---|---:|
| Peking University Third Hospital | 18 |
| Assistance Publique - Hopitaux de Paris | 17 |
| Massachusetts General Hospital | 13 |
| University of Michigan | 11 |
| Drexel University College of Medicine | 10 |
| Mayo Clinic | 9 |
| Johns Hopkins University | 8 |
| University of Miami | 8 |

Pharmaceutical Companies

| Company | ALS Trials | Notable Programs |
|---|---|---|
| Biogen | 8 | ASO therapies, C9orf72 |
| Cytokinetics | 8 | Tirasemtiv, reldesemtiv |
| Knopp Biosciences | 9 | KD7000 series |
| Amylyx Pharmaceuticals | 5 | AMX0035 (approved) |
| Neuralstem | 4 | Cell therapy |
| Roche | 3 | Genentech collaboration |

Gap Analysis

Underexplored Areas

Strategic Opportunities

Cross-Links to Related Pages

• [TDP-43 Proteinopathy - Mechanism Page](/mechanisms/tdp-43-proteinopathy)
• [ALS Investment Landscape](/investment/als)
• [FTD Investment Landscape](/investment/ftd)
• [TDP-43 Protein - Protein Page](/proteins/tdp-43-protein)
• [TARDBP Gene - Gene Page](/genes/tardbp)
• [LATE Disease - Limbic-Predominant Age-Related TDP-43 Encephalopathy](/diseases/late)

See Also

• [Amyotrophic Lateral Sclerosis (ALS) - Disease](/diseases/amyotrophic-lateral-sclerosis)
• [Frontotemporal Dementia (FTD) - Disease](/diseases/frontotemporal-dementia)
• [ALS vs FTD: Comparative Investment Analysis](/als-vs-ftd:-comparative-investment-analysis)
• [TDP-43 Biomarker](/biomarkers/tdp-43)

External Links

• [ClinicalTrials.gov - ALS Trials](https://clinicaltrials.gov/search?cond=amyotrophic+lateral+sclerosis)
• [ClinicalTrials.gov - FTD Trials](https://clinicaltrials.gov/search?cond=frontotemporal+dementia)
• [PubMed - TDP-43 Therapeutics](https://pubmed.ncbi.nlm.nih.gov/?term=TDP-43+therapeutics+ALS)

Clinical Trials

For current clinical trials targeting TDP-43 pathology in ALS and FTD, see:

• [Clinical Trials Index](/clinical-trials)

References